Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.
Wernig G, Kharas MG, Okabe R, Moore SA, Leeman DS, Cullen DE, Gozo M, McDowell EP, Levine RL, Doukas J, Mak CC, Noronha G, Martin M, Ko YD, Lee BH, Soll RM, Tefferi A, Hood JD, Gilliland DG. Wernig G, et al. Among authors: mak cc. Cancer Cell. 2008 Apr;13(4):311-20. doi: 10.1016/j.ccr.2008.02.009. Cancer Cell. 2008. PMID: 18394554 Free article.
The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models.
Tam BY, Chiu K, Chung H, Bossard C, Nguyen JD, Creger E, Eastman BW, Mak CC, Ibanez M, Ghias A, Cahiwat J, Do L, Cho S, Nguyen J, Deshmukh V, Stewart J, Chen CW, Barroga C, Dellamary L, Kc SK, Phalen TJ, Hood J, Cha S, Yazici Y. Tam BY, et al. Among authors: mak cc. Cancer Lett. 2020 Mar 31;473:186-197. doi: 10.1016/j.canlet.2019.09.009. Epub 2019 Sep 24. Cancer Lett. 2020. PMID: 31560935 Free article.
Inhibitors of ABL and the ABL-T315I mutation.
Noronha G, Cao J, Chow CP, Dneprovskaia E, Fine RM, Hood J, Kang X, Klebansky B, Lohse D, Mak CC, McPherson A, Palanki MS, Pathak VP, Renick J, Soll R, Zeng B. Noronha G, et al. Among authors: mak cc. Curr Top Med Chem. 2008;8(10):905-21. doi: 10.2174/156802608784911635. Curr Top Med Chem. 2008. PMID: 18673174
Discovery and preliminary structure-activity relationship studies of novel benzotriazine based compounds as Src inhibitors.
Noronha G, Barrett K, Cao J, Dneprovskaia E, Fine R, Gong X, Gritzen C, Hood J, Kang X, Klebansky B, Li G, Liao W, Lohse D, Mak CC, McPherson A, Palanki MS, Pathak VP, Renick J, Soll R, Splittgerber U, Wrasidlo W, Zeng B, Zhao N, Zhou Y. Noronha G, et al. Among authors: mak cc. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5546-50. doi: 10.1016/j.bmcl.2006.08.035. Epub 2006 Aug 22. Bioorg Med Chem Lett. 2006. PMID: 16931012
Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinase inhibitor with anti-tumor activity in preclinical assays.
Noronha G, Barrett K, Boccia A, Brodhag T, Cao J, Chow CP, Dneprovskaia E, Doukas J, Fine R, Gong X, Gritzen C, Gu H, Hanna E, Hood JD, Hu S, Kang X, Key J, Klebansky B, Kousba A, Li G, Lohse D, Mak CC, McPherson A, Palanki MS, Pathak VP, Renick J, Shi F, Soll R, Splittgerber U, Stoughton S, Tang S, Yee S, Zeng B, Zhao N, Zhu H. Noronha G, et al. Among authors: mak cc. Bioorg Med Chem Lett. 2007 Feb 1;17(3):602-8. doi: 10.1016/j.bmcl.2006.11.006. Epub 2006 Nov 7. Bioorg Med Chem Lett. 2007. PMID: 17113292
The design and preliminary structure-activity relationship studies of benzotriazines as potent inhibitors of Abl and Abl-T315I enzymes.
Cao J, Fine R, Gritzen C, Hood J, Kang X, Klebansky B, Lohse D, Mak CC, McPherson A, Noronha G, Palanki MS, Pathak VP, Renick J, Soll R, Zeng B, Zhu H. Cao J, et al. Among authors: mak cc. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5812-8. doi: 10.1016/j.bmcl.2007.08.043. Epub 2007 Aug 25. Bioorg Med Chem Lett. 2007. PMID: 17827012
Development of prodrug 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl benzoate (TG100801): a topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degeneration.
Palanki MS, Akiyama H, Campochiaro P, Cao J, Chow CP, Dellamary L, Doukas J, Fine R, Gritzen C, Hood JD, Hu S, Kachi S, Kang X, Klebansky B, Kousba A, Lohse D, Mak CC, Martin M, McPherson A, Pathak VP, Renick J, Soll R, Umeda N, Yee S, Yokoi K, Zeng B, Zhu H, Noronha G. Palanki MS, et al. Among authors: mak cc. J Med Chem. 2008 Mar 27;51(6):1546-59. doi: 10.1021/jm7011276. Epub 2008 Feb 27. J Med Chem. 2008. PMID: 18311895
Development of novel benzotriazines for drug discovery.
Palanki MS, Cao J, Chow CP, Dneprovskaia E, Mak CC, McPherson A, Pathak VP, Renick J, Soll R, Zeng B, Noronha G. Palanki MS, et al. Among authors: mak cc. Expert Opin Drug Discov. 2009 Jan;4(1):33-49. doi: 10.1517/17460440802580536. Epub 2008 Dec 10. Expert Opin Drug Discov. 2009. PMID: 23480335
89 results